| Drug Name |
Eletriptan hydrobromide |
| Drug ID |
BADD_D00756 |
| Description |
Eletriptan is a second generation triptan drug developed by Pfizer Inc for the treatment of migraine headaches. |
| Indications and Usage |
For the acute treatment of migraine with or without aura in adults. |
| Marketing Status |
Prescription |
| ATC Code |
N02CC06 |
| DrugBank ID |
DB00216
|
| KEGG ID |
D01973
|
| MeSH ID |
C115647
|
| PubChem ID |
656631
|
| TTD Drug ID |
D02DMQ
|
| NDC Product Code |
71335-1830; 48087-0090; 27241-040; 0378-4288; 68382-923; 48087-0102; 65162-042; 59651-105; 65977-0059; 59651-104; 10829-0558; 0049-2340; 0049-2330; 65015-719; 65162-043; 70771-1107; 59762-2321; 0378-4287; 70771-1108; 68382-922; 10829-0557; 0093-8310; 63629-8320; 63126-904; 27241-039; 59651-101; 0093-8311; 59762-2322 |
| Synonyms |
eletriptan | (R)-3-((1-methyl-2-pyrrolidinyl)methyl)-5-(2-(phenylsulfonyl)ethyl)-1H-indole | UK 166,044 | UK-166044 | UK 166044 | UK-166,044 | Relpax | UK-116044-04 | UK-116,044-04 | eletriptan hydrobromide | (R)-3-((1-methyl-2-pyrrolidinyl)methyl)-5-(2-(phenylsulfonyl)ethyl)-1H-indole monohydrobromide | 3-(1-methyl-2-pyrrolidinylmethyl)-5-(2-(phenylsulfonyl)ethyl)-1H-indole hydrobromide |
